Looks like we're on schedule..anti-vaxers lament--oh well..they can always blame it on the chem-trails...LOL!
In December, Pfizer-BioNTech and Moderna vaccines were cleared in the U.S. Yet initial supplies were limited and the rollout started haltingly. States restricted doses to certain groups, such as the elderly, healthcare workers and people with high-risk medical conditions.
Both the production and administration of shots have picked up in recent weeks, however. Now, some 2.5 million people in the U.S. are vaccinated daily on average, up from about 500,000 in early January, though many who want a vaccine still can’t get it.
The increased output should be enough to fully vaccinate 76 million people in the U.S. in March, another 75 million in April and then 89 million more in May, according to estimates from Evercore ISI analysts. The Pfizer-BioNTech and Moderna vaccines require two doses.
By midsummer, 75% of Americans 12 years old and above should be vaccinated, according to Morgan Stanley. The vaccines aren’t currently authorized for anyone younger than 16, but companies may have results this spring for studies of the shots in adolescents 12 and older, which, if positive, could lead to vaccinations for that age group. The companies are also starting to test the vaccines in children younger than 12, but results of those studies aren’t expected until late this year.
With production ramping up, President Biden said March 11 that he wants states to widen eligibility to all adults by May 1 and has said the U.S. should have enough supply for all adults by the end of May.
In December, Pfizer-BioNTech and Moderna vaccines were cleared in the U.S. Yet initial supplies were limited and the rollout started haltingly. States restricted doses to certain groups, such as the elderly, healthcare workers and people with high-risk medical conditions.
Both the production and administration of shots have picked up in recent weeks, however. Now, some 2.5 million people in the U.S. are vaccinated daily on average, up from about 500,000 in early January, though many who want a vaccine still can’t get it.
The increased output should be enough to fully vaccinate 76 million people in the U.S. in March, another 75 million in April and then 89 million more in May, according to estimates from Evercore ISI analysts. The Pfizer-BioNTech and Moderna vaccines require two doses.
By midsummer, 75% of Americans 12 years old and above should be vaccinated, according to Morgan Stanley. The vaccines aren’t currently authorized for anyone younger than 16, but companies may have results this spring for studies of the shots in adolescents 12 and older, which, if positive, could lead to vaccinations for that age group. The companies are also starting to test the vaccines in children younger than 12, but results of those studies aren’t expected until late this year.
With production ramping up, President Biden said March 11 that he wants states to widen eligibility to all adults by May 1 and has said the U.S. should have enough supply for all adults by the end of May.